Opposite Remodeling of Peripheral Blood Dual TCR T Cell Responses Induced by SABR and icSABR in Early-Stage Non-Small Cell Lung Cancer: A Single-Cell Analysis Based on scRNA-seq and TCR-seq

Authors:
  • HYHongxia Yang
    Hongxia Yang
  • KQKai Quan
    Kai Quan
  • PSPeng Su
    Peng Su
  • YXYuanyuan Xu
    Yuanyuan Xu
  • DCDawei Cheng
    Dawei Cheng

Abstract
This study aimed to clarify the differential regulatory effects of stereotactic ablative radiotherapy (SABR) and immunotherapy administered prior to SABR (icSABR) on dual TCR T cells, a distinct T cell subset. we performed a systematic analysis of the proportion, clonal architecture, subset distribution, transcriptional profiles, and clonal repertoires of peripheral blood dual TCR T cells before and after treatment in 6 patients with early-stage non-small cell lung cancer (NSCLC), including 4 patients in the SABR group and 2 in the icSABR group. The results showed that after SABR treatment, the overall proportion of dual TCR T cells decreased along with reduced clonal diversity; the proportions of dual TCR T cells within CD8⁺ and CD4⁺ effector T cell subsets were elevated, accompanied by enhanced cytotoxic function and enrichment of the interferon-α response pathway, while the proportion of dual TCR Tregs and their suppressive score declined; meanwhile, shared clonotypes with increased abundance post-treatment were identified, which shared partial complementarity-determining region 3 (CDR3) sequences with single TCR T cells. In contrast, icSABR treatment exerted opposite effects: the overall proportion of dual TCR T cells increased with a rise in the monoclonal fraction; the proportions of dual TCR T cells in effector subsets decreased, with attenuated cytotoxic function and downregulated interferon response pathway, while the proportion of dual TCR Tregs and their suppressive score increased, and no shared clonotypes were detected between pre- and post-treatment samples. These findings suggest that SABR may drive clonal expansion and functional reactivation of dual TCR effector T cells via tumor antigen release to participate in anti-tumor immunity, whereas pre-radiotherapy immunotherapy may reshape the response pattern of dual TCR T cells, indicating that dual TCR T cells may serve as potential promising candidate for future investigation for evaluating SABR-induced immune responses and optimizing radiotherapy-immunotherapy combination strategies.